Pharmacologic classification: thrombopoietin receptor agonist
Therapeutic classification: antithrombocytopenic
Pregnancy risk category: C
AVAILABLE FORMS
Injection: 250 mcg, 500 mcg single-use vials
INDICATIONS AND DOSAGES
Thrombocytopenia in patients with chronic immune idiopathic thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy—
Adults: Initially, 1 mcg/kg subcutaneously once weekly. Adjust dose as needed in increments of 1 mcg/kg to maintain platelet count of 50 × 109/L or higher (to reduce the risk of bleeding). Maximum dose is 10 mcg/kg. Withhold drug if platelet count exceeds 400 × 109/L. Stop drug if platelet count doesn't increase after 4 weeks of therapy at the maximum dose.
CONTRAINDICATIONS AND CAUTIONS
Use cautiously in pregnant or breast-feeding patients.
INTERACTIONS
None reported.
ADVERSE REACTIONS
CNS: dizziness, headache, insomnia, paresthesia.
GI: abdominal pain, dyspepsia.
Musculoskeletal: arthralgia, extremity pain, myalgia, shoulder pain.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
romiplostim